Amgen Inc. (NASDAQ:AMGN) EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $185.95, for a total transaction of $283,573.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Amgen Inc. (NASDAQ AMGN) traded up 0.18% during midday trading on Tuesday, reaching $185.79. 2,036,369 shares of the company’s stock were exchanged. The firm has a market capitalization of $135.57 billion, a P/E ratio of 16.92 and a beta of 1.36. The stock’s 50 day moving average is $182.35 and its 200 day moving average is $170.56. Amgen Inc. has a 52 week low of $133.64 and a 52 week high of $191.10.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The company had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. During the same period in the previous year, the firm earned $2.84 earnings per share. Amgen’s revenue for the quarter was up 2.1% on a year-over-year basis. On average, analysts expect that Amgen Inc. will post $12.58 EPS for the current fiscal year.

WARNING: “Sean E. Harper Sells 1,525 Shares of Amgen Inc. (AMGN) Stock” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/10/10/sean-e-harper-sells-1525-shares-of-amgen-inc-amgn-stock.html.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jackson Grant Investment Advisers Inc. lifted its position in shares of Amgen by 0.6% during the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after purchasing an additional 4 shares in the last quarter. Financial Advisory Service Inc. lifted its position in shares of Amgen by 0.3% during the second quarter. Financial Advisory Service Inc. now owns 1,974 shares of the medical research company’s stock worth $340,000 after purchasing an additional 5 shares in the last quarter. Capital Advisors Ltd. LLC lifted its position in shares of Amgen by 0.6% during the second quarter. Capital Advisors Ltd. LLC now owns 1,103 shares of the medical research company’s stock worth $190,000 after purchasing an additional 7 shares in the last quarter. Ballentine Partners LLC lifted its position in shares of Amgen by 0.3% during the second quarter. Ballentine Partners LLC now owns 3,441 shares of the medical research company’s stock worth $620,000 after purchasing an additional 9 shares in the last quarter. Finally, Hudock Capital Group LLC lifted its position in shares of Amgen by 0.5% during the second quarter. Hudock Capital Group LLC now owns 1,921 shares of the medical research company’s stock worth $330,000 after purchasing an additional 10 shares in the last quarter. Institutional investors own 78.10% of the company’s stock.

Several analysts have recently weighed in on AMGN shares. Morgan Stanley increased their price target on shares of Amgen from $183.00 to $184.00 and gave the company an “overweight” rating in a research note on Tuesday, June 13th. Oppenheimer Holdings, Inc. set a $189.00 price target on shares of Amgen and gave the company a “buy” rating in a research note on Tuesday, June 13th. UBS AG reissued a “neutral” rating and issued a $175.00 price target (up previously from $174.00) on shares of Amgen in a research note on Tuesday, June 13th. Leerink Swann reissued a “market perform” rating and issued a $161.00 price target on shares of Amgen in a research note on Thursday, June 22nd. Finally, Deutsche Bank AG started coverage on shares of Amgen in a research note on Friday, June 23rd. They issued a “hold” rating and a $172.00 price target for the company. Ten investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $189.99.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.